TABLE 2.
Sequences of primers used in this study
| Primer | Sequencea (5′ → 3′) |
|---|---|
| hynL-1-f | GAATTCTAGATGGCAACAACACAGCGCGTC |
| hynL-1-r | GATAGCATGCTTATTTGACCTTCACCTGCACG |
| pUC19-f | GCCAGGGTTTTCCCAGTCACGA |
| pUC19-r | GAGCGGATAACAATTTCACACAGG |
| kanP-f | AAAGCCACGTTGTGTCTC |
| kanP-r | GAATGTTAACACCCCTTGTATTACTG |
| hynL-hupE-f | phos-ATGGCAACAACACAGCGC |
| hynL-hupE-r | phos-TCACAGCCCGAGGATGAGG |
| EZ-Tn5-fb | ACCTACAACAAAGCTCTCATCAACC |
| EZ-Tn5-rb | GCAATGTAACATCAGAGATTTTGAG |
| pMOD2-PCR-fb | ATTCAGGCTGCGCAACTGGT |
| pMOD2-PCR-rb | GTCAGTGAGCGAGGAAGCGGAAG |
| pMOD2-Seq-fb | GCCAACGACTACGCACTAGCCAAC |
| pMOD2-Seq-rb | GAGCCAATATGCGAGAACACCCGAGAA |
| hynL-2-f | TCATGGCGGAGCATCTGGAG |
| hynL-2-r | CGTATTTCGGAACATGGGTGG |
| hydA-f | GAATGGTACCCAGTTCAACATGCTCTACCT |
| hydA-r | GATAGGTACCTTGAACGGCGCGTCGAACTG |
a
phos denotes phosphorylated ends. Relevant restriction sites are underlined.
b
EPICENTRE Biotechnologies, Madison, WI.